ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Cancer Victims Support Sen. Richard Blumenthal in Urging Johnson & Johnson to Accept Responsibility

Senator cites bipartisan agreement on need for action

At a recent news conference, Sen. Richard Blumenthal, D-Conn., flanked by ovarian cancer victims Lynn Skoda and Joan Kiley, sharply criticized Johnson & Johnson (NYSE: JNJ) for its role in the spread of cancer through its talcum powder products.

Ms. Kiley conveyed her emotional story, holding a photograph of her loved ones taken during her chemotherapy for ovarian cancer. Her account emphasized the broad impact of Johnson & Johnson's alleged negligence, highlighting the collective suffering of many families.

Sen. Blumenthal attacked J&J’s evasive legal maneuvering, known as the "Texas Two-Step." He detailed how in October 2021 Johnson & Johnson moved its litigation liabilities from the talc lawsuits to a subsidiary called LTL Management without providing assets sufficient to address the basic economic damages of individual claimants.

Sen. Blumenthal spotlighted the bipartisan nature of the concern surrounding this issue. "The Judiciary Committee recently convened a hearing on this situation,” he said. “There was a clear bipartisan agreement on the urgency to address the matter. Both Republicans and Democrats recognize that this situation demands action, potentially in the form of new legislation. In the interim, companies like Johnson & Johnson should step forward and provide justice."

“From Main Street to Wall Street, it’s obvious the pendulum has swung against massively profitable corporations attempting to use bankruptcy to avoid responsibility for their defective products,” said attorney Andy Birchfield, head of the Mass Torts Section at the Beasley Allen Law Firm, who has led the fight on behalf of cancer victims to oppose J&J’s attempt to revictimize tens of thousands of women with ovarian cancer who are fighting for their lives. “We appreciate Sen. Blumenthal’s commitment to justice along with legislators from both parties who join us in saying ‘no’ to this kind of corporate abuse.”

Despite Johnson & Johnson's impressive revenue of more than $97 billion in 2022, the company has unsuccessfully sought bankruptcy to force claimants to accept a proposed settlement of $8.9 billion, an amount grossly insufficient to cover even basic medical expenses for victims and their families. Reportedly, the company is considering filing for bankruptcy a third time, after courts dismissed its first two bankruptcy filings ruling, they were made in bad faith.

At the news conference, the senator expressed admiration for Ms. Skoda and Ms. Kiley, noting that their cancers are believed to be linked to talcum powder distributed by Johnson & Johnson. Sen. Blumenthal emphasized that Johnson’s Baby Powder, which independent testing showed contains asbestos, has been associated with the suffering of tens of thousands of women, due in part to the company's failure to issue sufficient warnings.

Ms. Skoda recounted her own battle with stage three ovarian cancer beginning in 2017, detailing the extensive medical procedures that often accompany treatment. Later, DNA testing showed she had no genetic predisposition to ovarian cancer, suggesting her exposure to talcum powder as an infant may be the cause of her illness.

“Sen. Blumenthal is part of a growing chorus of concerned lawmakers challenging Johnson & Johnson to rise to the occasion,” said Mr. Birchfield. “We believe it’s essential that our leaders reinforce that J&J has a moral and legal obligation to address the harm caused by the company’s talcum powder products.”

For the complete press conference, watch the video.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.43
+1.08 (0.48%)
AAPL  270.97
-2.70 (-0.99%)
AMD  214.95
+1.52 (0.71%)
BAC  55.88
+0.61 (1.10%)
GOOG  311.33
+2.72 (0.88%)
META  661.50
+2.73 (0.41%)
MSFT  484.92
-1.00 (-0.21%)
NVDA  183.69
+2.70 (1.49%)
ORCL  198.38
+6.41 (3.34%)
TSLA  488.73
+7.53 (1.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.